No Data
Hima Medical received an increase in shareholding of 0.348 million shares of the company's stock from the CEO and executive director, Lin Shunchao.
Sihuan Pharmaceutical Holdings Group Ltd. (03309) announced that the board of directors of the company was informed by the company's chairman, CEO and executive director, Lin Shunchao, that he had purchased a total of 0.348 million shares of the company's stock in the market on July 22, 2024, at a total cost of HKD 0.9203 million, equivalent to an average price of about HKD 2.64 per share and accounting for approximately 0.028% of the company's issued share capital.
Hima Medical (03309.HK) received Chairman, CEO and Executive Director Lin Shunchao's shareholding of 0.358 million shares.
Hithink RoyalFlush announced on July 19th that the Board of Directors was informed by the Chairman, CEO and Executive Director, Lin Shunchao, that he had purchased a total of 0.358 million shares of the company on the market since July 18, 2024, at a total cost of HKD 949,940, which is an average price of approximately HKD 2.65 per share and accounts for approximately 0.029% of the company's issued share capital.
Hima Medical received an increase in shareholding of 0.792 million shares by the Executive Director and CEO Lin Shunchao.
Hima Medical (03309) announced that the Board of Directors (Board of Directors) of the company has been informed by Dr. Lin Shunchao, the chairman, CEO and executive director of the company, that he has purchased a total of 0.792 million shares of the company's stock on the market since July 15, 2024, at a total cost of HKD 2.077 million, with an average price of about HKD 2.62 per share (for the purchase from July 15 to July 17), accounting for approximately 0.063% of the company's issued share capital. Prior to the purchase from July 15 to July 17, Dr. Lin, together with Hima Group Limited (the company's controlling shareholder)
Express News | C-Mer Eye Care - CEO Purchased 792,000 Shares of Co for HK$2.1 Mln
C-MER Medical Renews Lease for Shenzhen Eye Hospital Property
Hima Medical (03309.HK): Shenzhen Hima Hospital Renews Lease.
On July 15th, Gelonhui reported that the existing lease agreement for the Shenzhen property where Hima Medical's ophthalmic hospital operates will expire on July 31, 2024. On July 15, 2024, Shenzhen Hima Hospital entered into a new lease agreement, whereby Shenzhen Maida and Shenzhen Hima Hospital extended the term of the lease for Shenzhen Property for 36 months. Based on the new lease agreement effective from August 1, 2024, the Group will recognize the lease as the right-of-use asset. Based on the preliminary assessment by the company's management (which has not been reviewed or audited by the company's auditors), Shenzhen Property will ...
C-MER Eye Care Holdings (HKG:3309 Investor Three-year Losses Grow to 49% as the Stock Sheds HK$449m This Past WeekNo Data
